Safety and efficacy of ustekinumab or golimumab in patients with chronic sarcoidosis.
Identifieur interne : 001483 ( PubMed/Corpus ); précédent : 001482; suivant : 001484Safety and efficacy of ustekinumab or golimumab in patients with chronic sarcoidosis.
Auteurs : Marc A. Judson ; Robert P. Baughman ; Ulrich Costabel ; Marjolein Drent ; Kevin F. Gibson ; Ganesh Raghu ; Hidenobu Shigemitsu ; Joseph B. Barney ; Daniel A. Culver ; Nabeel Y. Hamzeh ; Marlies S. Wijsenbeek ; Carlo Albera ; Isham Huizar ; Prasheen Agarwal ; Carrie Brodmerkel ; Rosemary Watt ; Elliot S. BarnathanSource :
- The European respiratory journal [ 1399-3003 ] ; 2014.
English descriptors
- KwdEn :
- Adult, Antibodies, Monoclonal (therapeutic use), Antibodies, Monoclonal, Humanized (therapeutic use), Antirheumatic Agents (therapeutic use), Chronic Disease, Double-Blind Method, Female, Humans, Interleukin-12 (antagonists & inhibitors), Interleukin-23 (antagonists & inhibitors), Male, Middle Aged, Sarcoidosis (drug therapy), Sarcoidosis (physiopathology), Tumor Necrosis Factor-alpha (antagonists & inhibitors), Ustekinumab.
- MESH :
- chemical , antagonists & inhibitors : Interleukin-12, Interleukin-23, Tumor Necrosis Factor-alpha.
- chemical , therapeutic use : Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized, Antirheumatic Agents.
- drug therapy : Sarcoidosis.
- physiopathology : Sarcoidosis.
- Adult, Chronic Disease, Double-Blind Method, Female, Humans, Male, Middle Aged, Ustekinumab.
Abstract
Sarcoidosis is characterised by non-caseating granulomas that secrete pro-inflammatory cytokines, including interleukin (IL)-12, IL-23, and tumour necrosis factor (TNF)-α. Ustekinumab and golimumab are monoclonal antibodies that specifically inhibit IL-12/IL-23 and TNF-α, respectively. Patients with chronic pulmonary sarcoidosis (lung group) and/or skin sarcoidosis (skin group) received either 180 mg ustekinumab at week 0 followed by 90 mg every 8 weeks, 200 mg golimumab at week 0 followed by 100 mg every 4 weeks, or placebo. Patients underwent corticosteroid tapering between weeks 16 and 28. The primary end-point was week 16 change in percentage predicted forced vital capacity (ΔFVC % pred) in the lung group. Major secondary end-points were: week 28 for ΔFVC % pred, 6-min walking distance, St George's Respiratory Questionnaire (lung group), and Skin Physician Global Assessment response (skin group). At week 16, no significant differences were observed in ΔFVC % pred with ustekinumab (-0.15, p = 0.13) or golimumab (1.15, p = 0.54) compared with placebo (2.02). At week 28, there were no significant improvements in the major secondary end-points, although a nonsignificant numerically greater Skin Physician Global Assessment response was observed following golimumab treatment (53%) when compared with the placebo (30%). Serious adverse events were similar in all treatment groups. Although treatment was well tolerated, neither ustekinumab nor golimumab demonstrated efficacy in pulmonary sarcoidosis. However, trends towards improvement were observed with golimumab in some dermatological end-points.
DOI: 10.1183/09031936.00000914
PubMed: 25034562
Links to Exploration step
pubmed:25034562Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Safety and efficacy of ustekinumab or golimumab in patients with chronic sarcoidosis.</title><author><name sortKey="Judson, Marc A" sort="Judson, Marc A" uniqKey="Judson M" first="Marc A" last="Judson">Marc A. Judson</name><affiliation><nlm:affiliation>Dept of Medicine, Albany Medical College, Albany, NY, USA judsonm@mail.amc.edu.</nlm:affiliation></affiliation></author><author><name sortKey="Baughman, Robert P" sort="Baughman, Robert P" uniqKey="Baughman R" first="Robert P" last="Baughman">Robert P. Baughman</name><affiliation><nlm:affiliation>Dept of Internal Medicine, University of Cincinnati Medical Center, Cincinnati, OH, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Costabel, Ulrich" sort="Costabel, Ulrich" uniqKey="Costabel U" first="Ulrich" last="Costabel">Ulrich Costabel</name><affiliation><nlm:affiliation>Ruhrlandklinik and University of Duisburg-Essen, Essen, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Drent, Marjolein" sort="Drent, Marjolein" uniqKey="Drent M" first="Marjolein" last="Drent">Marjolein Drent</name><affiliation><nlm:affiliation>Dept of Interstitial Lung Diseases, Gelderse Vallei Hospital, Ede, The Netherlands.</nlm:affiliation></affiliation></author><author><name sortKey="Gibson, Kevin F" sort="Gibson, Kevin F" uniqKey="Gibson K" first="Kevin F" last="Gibson">Kevin F. Gibson</name><affiliation><nlm:affiliation>Division of Pulmonary, Allergy and Critical Care Medicine, University of Pittsburgh, Pittsburgh, PA, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Raghu, Ganesh" sort="Raghu, Ganesh" uniqKey="Raghu G" first="Ganesh" last="Raghu">Ganesh Raghu</name><affiliation><nlm:affiliation>Division of Pulmonary and Critical Care Medicine, University of Washington, Seattle, WA, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Shigemitsu, Hidenobu" sort="Shigemitsu, Hidenobu" uniqKey="Shigemitsu H" first="Hidenobu" last="Shigemitsu">Hidenobu Shigemitsu</name><affiliation><nlm:affiliation>University of Southern California, Los Angeles, CA, USA Division of Pulmonary and Critical Care Medicine, University of Nevada School of Medicine, Las Vegas, NV, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Barney, Joseph B" sort="Barney, Joseph B" uniqKey="Barney J" first="Joseph B" last="Barney">Joseph B. Barney</name><affiliation><nlm:affiliation>Pulmonary and Critical Care Medicine, University of Alabama, Birmingham, AL, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Culver, Daniel A" sort="Culver, Daniel A" uniqKey="Culver D" first="Daniel A" last="Culver">Daniel A. Culver</name><affiliation><nlm:affiliation>Pulmonary, Allergy and Critical Care Medicine, Cleveland Clinic Foundation, Cleveland, OH, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Hamzeh, Nabeel Y" sort="Hamzeh, Nabeel Y" uniqKey="Hamzeh N" first="Nabeel Y" last="Hamzeh">Nabeel Y. Hamzeh</name><affiliation><nlm:affiliation>Dept of Medicine, National Jewish Health, Denver, CO, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Wijsenbeek, Marlies S" sort="Wijsenbeek, Marlies S" uniqKey="Wijsenbeek M" first="Marlies S" last="Wijsenbeek">Marlies S. Wijsenbeek</name><affiliation><nlm:affiliation>Dept of Pulmonary Disease, Erasmus MC, University Hospital Rotterdam, Rotterdam, The Netherlands.</nlm:affiliation></affiliation></author><author><name sortKey="Albera, Carlo" sort="Albera, Carlo" uniqKey="Albera C" first="Carlo" last="Albera">Carlo Albera</name><affiliation><nlm:affiliation>Dept of Pulmonary Medicine, Erasmus Medical Centre, University Hospital Rotterdam, Rotterdam, The Netherlands.</nlm:affiliation></affiliation></author><author><name sortKey="Huizar, Isham" sort="Huizar, Isham" uniqKey="Huizar I" first="Isham" last="Huizar">Isham Huizar</name><affiliation><nlm:affiliation>Dept of Medicine, Texas Tech University Health Science Center, Lubbock, TX, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Agarwal, Prasheen" sort="Agarwal, Prasheen" uniqKey="Agarwal P" first="Prasheen" last="Agarwal">Prasheen Agarwal</name><affiliation><nlm:affiliation>Biostatistics, Janssen Research and Development, LLC, Spring House, PA, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Brodmerkel, Carrie" sort="Brodmerkel, Carrie" uniqKey="Brodmerkel C" first="Carrie" last="Brodmerkel">Carrie Brodmerkel</name><affiliation><nlm:affiliation>Immunology Biomarkers, Janssen Research and Development, LLC, Spring House, PA, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Watt, Rosemary" sort="Watt, Rosemary" uniqKey="Watt R" first="Rosemary" last="Watt">Rosemary Watt</name><affiliation><nlm:affiliation>Immunology, Janssen Research and Development, LLC, Spring House, PA, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Barnathan, Elliot S" sort="Barnathan, Elliot S" uniqKey="Barnathan E" first="Elliot S" last="Barnathan">Elliot S. Barnathan</name><affiliation><nlm:affiliation>Immunology, Janssen Research and Development, LLC, Spring House, PA, USA.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2014">2014</date><idno type="RBID">pubmed:25034562</idno><idno type="pmid">25034562</idno><idno type="doi">10.1183/09031936.00000914</idno><idno type="wicri:Area/PubMed/Corpus">001483</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001483</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Safety and efficacy of ustekinumab or golimumab in patients with chronic sarcoidosis.</title><author><name sortKey="Judson, Marc A" sort="Judson, Marc A" uniqKey="Judson M" first="Marc A" last="Judson">Marc A. Judson</name><affiliation><nlm:affiliation>Dept of Medicine, Albany Medical College, Albany, NY, USA judsonm@mail.amc.edu.</nlm:affiliation></affiliation></author><author><name sortKey="Baughman, Robert P" sort="Baughman, Robert P" uniqKey="Baughman R" first="Robert P" last="Baughman">Robert P. Baughman</name><affiliation><nlm:affiliation>Dept of Internal Medicine, University of Cincinnati Medical Center, Cincinnati, OH, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Costabel, Ulrich" sort="Costabel, Ulrich" uniqKey="Costabel U" first="Ulrich" last="Costabel">Ulrich Costabel</name><affiliation><nlm:affiliation>Ruhrlandklinik and University of Duisburg-Essen, Essen, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Drent, Marjolein" sort="Drent, Marjolein" uniqKey="Drent M" first="Marjolein" last="Drent">Marjolein Drent</name><affiliation><nlm:affiliation>Dept of Interstitial Lung Diseases, Gelderse Vallei Hospital, Ede, The Netherlands.</nlm:affiliation></affiliation></author><author><name sortKey="Gibson, Kevin F" sort="Gibson, Kevin F" uniqKey="Gibson K" first="Kevin F" last="Gibson">Kevin F. Gibson</name><affiliation><nlm:affiliation>Division of Pulmonary, Allergy and Critical Care Medicine, University of Pittsburgh, Pittsburgh, PA, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Raghu, Ganesh" sort="Raghu, Ganesh" uniqKey="Raghu G" first="Ganesh" last="Raghu">Ganesh Raghu</name><affiliation><nlm:affiliation>Division of Pulmonary and Critical Care Medicine, University of Washington, Seattle, WA, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Shigemitsu, Hidenobu" sort="Shigemitsu, Hidenobu" uniqKey="Shigemitsu H" first="Hidenobu" last="Shigemitsu">Hidenobu Shigemitsu</name><affiliation><nlm:affiliation>University of Southern California, Los Angeles, CA, USA Division of Pulmonary and Critical Care Medicine, University of Nevada School of Medicine, Las Vegas, NV, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Barney, Joseph B" sort="Barney, Joseph B" uniqKey="Barney J" first="Joseph B" last="Barney">Joseph B. Barney</name><affiliation><nlm:affiliation>Pulmonary and Critical Care Medicine, University of Alabama, Birmingham, AL, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Culver, Daniel A" sort="Culver, Daniel A" uniqKey="Culver D" first="Daniel A" last="Culver">Daniel A. Culver</name><affiliation><nlm:affiliation>Pulmonary, Allergy and Critical Care Medicine, Cleveland Clinic Foundation, Cleveland, OH, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Hamzeh, Nabeel Y" sort="Hamzeh, Nabeel Y" uniqKey="Hamzeh N" first="Nabeel Y" last="Hamzeh">Nabeel Y. Hamzeh</name><affiliation><nlm:affiliation>Dept of Medicine, National Jewish Health, Denver, CO, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Wijsenbeek, Marlies S" sort="Wijsenbeek, Marlies S" uniqKey="Wijsenbeek M" first="Marlies S" last="Wijsenbeek">Marlies S. Wijsenbeek</name><affiliation><nlm:affiliation>Dept of Pulmonary Disease, Erasmus MC, University Hospital Rotterdam, Rotterdam, The Netherlands.</nlm:affiliation></affiliation></author><author><name sortKey="Albera, Carlo" sort="Albera, Carlo" uniqKey="Albera C" first="Carlo" last="Albera">Carlo Albera</name><affiliation><nlm:affiliation>Dept of Pulmonary Medicine, Erasmus Medical Centre, University Hospital Rotterdam, Rotterdam, The Netherlands.</nlm:affiliation></affiliation></author><author><name sortKey="Huizar, Isham" sort="Huizar, Isham" uniqKey="Huizar I" first="Isham" last="Huizar">Isham Huizar</name><affiliation><nlm:affiliation>Dept of Medicine, Texas Tech University Health Science Center, Lubbock, TX, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Agarwal, Prasheen" sort="Agarwal, Prasheen" uniqKey="Agarwal P" first="Prasheen" last="Agarwal">Prasheen Agarwal</name><affiliation><nlm:affiliation>Biostatistics, Janssen Research and Development, LLC, Spring House, PA, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Brodmerkel, Carrie" sort="Brodmerkel, Carrie" uniqKey="Brodmerkel C" first="Carrie" last="Brodmerkel">Carrie Brodmerkel</name><affiliation><nlm:affiliation>Immunology Biomarkers, Janssen Research and Development, LLC, Spring House, PA, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Watt, Rosemary" sort="Watt, Rosemary" uniqKey="Watt R" first="Rosemary" last="Watt">Rosemary Watt</name><affiliation><nlm:affiliation>Immunology, Janssen Research and Development, LLC, Spring House, PA, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Barnathan, Elliot S" sort="Barnathan, Elliot S" uniqKey="Barnathan E" first="Elliot S" last="Barnathan">Elliot S. Barnathan</name><affiliation><nlm:affiliation>Immunology, Janssen Research and Development, LLC, Spring House, PA, USA.</nlm:affiliation></affiliation></author></analytic><series><title level="j">The European respiratory journal</title><idno type="eISSN">1399-3003</idno><imprint><date when="2014" type="published">2014</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Antibodies, Monoclonal (therapeutic use)</term><term>Antibodies, Monoclonal, Humanized (therapeutic use)</term><term>Antirheumatic Agents (therapeutic use)</term><term>Chronic Disease</term><term>Double-Blind Method</term><term>Female</term><term>Humans</term><term>Interleukin-12 (antagonists & inhibitors)</term><term>Interleukin-23 (antagonists & inhibitors)</term><term>Male</term><term>Middle Aged</term><term>Sarcoidosis (drug therapy)</term><term>Sarcoidosis (physiopathology)</term><term>Tumor Necrosis Factor-alpha (antagonists & inhibitors)</term><term>Ustekinumab</term></keywords><keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>Interleukin-12</term><term>Interleukin-23</term><term>Tumor Necrosis Factor-alpha</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antibodies, Monoclonal</term><term>Antibodies, Monoclonal, Humanized</term><term>Antirheumatic Agents</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Sarcoidosis</term></keywords><keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Sarcoidosis</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Chronic Disease</term><term>Double-Blind Method</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Ustekinumab</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Sarcoidosis is characterised by non-caseating granulomas that secrete pro-inflammatory cytokines, including interleukin (IL)-12, IL-23, and tumour necrosis factor (TNF)-α. Ustekinumab and golimumab are monoclonal antibodies that specifically inhibit IL-12/IL-23 and TNF-α, respectively. Patients with chronic pulmonary sarcoidosis (lung group) and/or skin sarcoidosis (skin group) received either 180 mg ustekinumab at week 0 followed by 90 mg every 8 weeks, 200 mg golimumab at week 0 followed by 100 mg every 4 weeks, or placebo. Patients underwent corticosteroid tapering between weeks 16 and 28. The primary end-point was week 16 change in percentage predicted forced vital capacity (ΔFVC % pred) in the lung group. Major secondary end-points were: week 28 for ΔFVC % pred, 6-min walking distance, St George's Respiratory Questionnaire (lung group), and Skin Physician Global Assessment response (skin group). At week 16, no significant differences were observed in ΔFVC % pred with ustekinumab (-0.15, p = 0.13) or golimumab (1.15, p = 0.54) compared with placebo (2.02). At week 28, there were no significant improvements in the major secondary end-points, although a nonsignificant numerically greater Skin Physician Global Assessment response was observed following golimumab treatment (53%) when compared with the placebo (30%). Serious adverse events were similar in all treatment groups. Although treatment was well tolerated, neither ustekinumab nor golimumab demonstrated efficacy in pulmonary sarcoidosis. However, trends towards improvement were observed with golimumab in some dermatological end-points.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">25034562</PMID><DateCreated><Year>2014</Year><Month>11</Month><Day>01</Day></DateCreated><DateCompleted><Year>2015</Year><Month>07</Month><Day>30</Day></DateCompleted><DateRevised><Year>2016</Year><Month>11</Month><Day>25</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1399-3003</ISSN><JournalIssue CitedMedium="Internet"><Volume>44</Volume><Issue>5</Issue><PubDate><Year>2014</Year><Month>Nov</Month></PubDate></JournalIssue><Title>The European respiratory journal</Title><ISOAbbreviation>Eur. Respir. J.</ISOAbbreviation></Journal><ArticleTitle>Safety and efficacy of ustekinumab or golimumab in patients with chronic sarcoidosis.</ArticleTitle><Pagination><MedlinePgn>1296-307</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1183/09031936.00000914</ELocationID><Abstract><AbstractText>Sarcoidosis is characterised by non-caseating granulomas that secrete pro-inflammatory cytokines, including interleukin (IL)-12, IL-23, and tumour necrosis factor (TNF)-α. Ustekinumab and golimumab are monoclonal antibodies that specifically inhibit IL-12/IL-23 and TNF-α, respectively. Patients with chronic pulmonary sarcoidosis (lung group) and/or skin sarcoidosis (skin group) received either 180 mg ustekinumab at week 0 followed by 90 mg every 8 weeks, 200 mg golimumab at week 0 followed by 100 mg every 4 weeks, or placebo. Patients underwent corticosteroid tapering between weeks 16 and 28. The primary end-point was week 16 change in percentage predicted forced vital capacity (ΔFVC % pred) in the lung group. Major secondary end-points were: week 28 for ΔFVC % pred, 6-min walking distance, St George's Respiratory Questionnaire (lung group), and Skin Physician Global Assessment response (skin group). At week 16, no significant differences were observed in ΔFVC % pred with ustekinumab (-0.15, p = 0.13) or golimumab (1.15, p = 0.54) compared with placebo (2.02). At week 28, there were no significant improvements in the major secondary end-points, although a nonsignificant numerically greater Skin Physician Global Assessment response was observed following golimumab treatment (53%) when compared with the placebo (30%). Serious adverse events were similar in all treatment groups. Although treatment was well tolerated, neither ustekinumab nor golimumab demonstrated efficacy in pulmonary sarcoidosis. However, trends towards improvement were observed with golimumab in some dermatological end-points.</AbstractText><CopyrightInformation>©ERS 2014.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Judson</LastName><ForeName>Marc A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Dept of Medicine, Albany Medical College, Albany, NY, USA judsonm@mail.amc.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baughman</LastName><ForeName>Robert P</ForeName><Initials>RP</Initials><AffiliationInfo><Affiliation>Dept of Internal Medicine, University of Cincinnati Medical Center, Cincinnati, OH, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Costabel</LastName><ForeName>Ulrich</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>Ruhrlandklinik and University of Duisburg-Essen, Essen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Drent</LastName><ForeName>Marjolein</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Dept of Interstitial Lung Diseases, Gelderse Vallei Hospital, Ede, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gibson</LastName><ForeName>Kevin F</ForeName><Initials>KF</Initials><AffiliationInfo><Affiliation>Division of Pulmonary, Allergy and Critical Care Medicine, University of Pittsburgh, Pittsburgh, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Raghu</LastName><ForeName>Ganesh</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Division of Pulmonary and Critical Care Medicine, University of Washington, Seattle, WA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shigemitsu</LastName><ForeName>Hidenobu</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>University of Southern California, Los Angeles, CA, USA Division of Pulmonary and Critical Care Medicine, University of Nevada School of Medicine, Las Vegas, NV, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barney</LastName><ForeName>Joseph B</ForeName><Initials>JB</Initials><AffiliationInfo><Affiliation>Pulmonary and Critical Care Medicine, University of Alabama, Birmingham, AL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Culver</LastName><ForeName>Daniel A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>Pulmonary, Allergy and Critical Care Medicine, Cleveland Clinic Foundation, Cleveland, OH, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hamzeh</LastName><ForeName>Nabeel Y</ForeName><Initials>NY</Initials><AffiliationInfo><Affiliation>Dept of Medicine, National Jewish Health, Denver, CO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wijsenbeek</LastName><ForeName>Marlies S</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>Dept of Pulmonary Disease, Erasmus MC, University Hospital Rotterdam, Rotterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Albera</LastName><ForeName>Carlo</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Dept of Pulmonary Medicine, Erasmus Medical Centre, University Hospital Rotterdam, Rotterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huizar</LastName><ForeName>Isham</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Dept of Medicine, Texas Tech University Health Science Center, Lubbock, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Agarwal</LastName><ForeName>Prasheen</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Biostatistics, Janssen Research and Development, LLC, Spring House, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brodmerkel</LastName><ForeName>Carrie</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Immunology Biomarkers, Janssen Research and Development, LLC, Spring House, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Watt</LastName><ForeName>Rosemary</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Immunology, Janssen Research and Development, LLC, Spring House, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barnathan</LastName><ForeName>Elliot S</ForeName><Initials>ES</Initials><AffiliationInfo><Affiliation>Immunology, Janssen Research and Development, LLC, Spring House, PA, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT00955279</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D017427">Clinical Trial, Phase II</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>07</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Eur Respir J</MedlineTA><NlmUniqueID>8803460</NlmUniqueID><ISSNLinking>0903-1936</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D061067">Antibodies, Monoclonal, Humanized</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018501">Antirheumatic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053759">Interleukin-23</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014409">Tumor Necrosis Factor-alpha</NameOfSubstance></Chemical><Chemical><RegistryNumber>187348-17-0</RegistryNumber><NameOfSubstance UI="D018664">Interleukin-12</NameOfSubstance></Chemical><Chemical><RegistryNumber>91X1KLU43E</RegistryNumber><NameOfSubstance UI="C529000">golimumab</NameOfSubstance></Chemical><Chemical><RegistryNumber>FU77B4U5Z0</RegistryNumber><NameOfSubstance UI="D000069549">Ustekinumab</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Eur Respir J. 2014 Nov;44(5):1123-6</RefSource><PMID Version="1">25362122</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000911" MajorTopicYN="N">Antibodies, Monoclonal</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D061067" MajorTopicYN="N">Antibodies, Monoclonal, Humanized</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018501" MajorTopicYN="N">Antirheumatic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002908" MajorTopicYN="N">Chronic Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018664" MajorTopicYN="N">Interleukin-12</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists & inhibitors</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053759" MajorTopicYN="N">Interleukin-23</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists & inhibitors</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012507" MajorTopicYN="N">Sarcoidosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014409" MajorTopicYN="N">Tumor Necrosis Factor-alpha</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists & inhibitors</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000069549" MajorTopicYN="N">Ustekinumab</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>7</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>7</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>8</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25034562</ArticleId><ArticleId IdType="pii">09031936.00000914</ArticleId><ArticleId IdType="doi">10.1183/09031936.00000914</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Amérique/explor/PittsburghV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001483 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 001483 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Amérique
|area= PittsburghV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:25034562
|texte= Safety and efficacy of ustekinumab or golimumab in patients with chronic sarcoidosis.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:25034562" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a PittsburghV1
| This area was generated with Dilib version V0.6.38. |  |